305 related articles for article (PubMed ID: 18791168)
1. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.
Springs AE; Karmaus PW; Crawford RB; Kaplan BL; Kaminski NE
J Leukoc Biol; 2008 Dec; 84(6):1574-84. PubMed ID: 18791168
[TBL] [Abstract][Full Text] [Related]
2. Differential modulation by delta9-tetrahydrocannabinol (∆9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.
Ngaotepprutaram T; Kaplan BL; Crawford RB; Kaminski NE
J Neuroimmune Pharmacol; 2012 Dec; 7(4):969-80. PubMed ID: 22851303
[TBL] [Abstract][Full Text] [Related]
3. Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.
Chen W; Crawford RB; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2015 Jun; 10(2):344-55. PubMed ID: 25900076
[TBL] [Abstract][Full Text] [Related]
4. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT).
Kaplan BL; Springs AE; Kaminski NE
Biochem Pharmacol; 2008 Sep; 76(6):726-37. PubMed ID: 18656454
[TBL] [Abstract][Full Text] [Related]
5. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
6. Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events.
Karmaus PW; Chen W; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2012 Dec; 7(4):843-55. PubMed ID: 21789506
[TBL] [Abstract][Full Text] [Related]
7. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.
McKallip RJ; Nagarkatti M; Nagarkatti PS
J Immunol; 2005 Mar; 174(6):3281-9. PubMed ID: 15749859
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
9. CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection.
Newton CA; Chou PJ; Perkins I; Klein TW
J Neuroimmune Pharmacol; 2009 Mar; 4(1):92-102. PubMed ID: 18792785
[TBL] [Abstract][Full Text] [Related]
10. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol.
Buchweitz JP; Karmaus PW; Williams KJ; Harkema JR; Kaminski NE
J Leukoc Biol; 2008 Mar; 83(3):785-96. PubMed ID: 18073275
[TBL] [Abstract][Full Text] [Related]
11. Similarities and differences upon binding of naturally occurring Δ
Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R
Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399
[TBL] [Abstract][Full Text] [Related]
12. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
14. Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2.
Karmaus PW; Chen W; Crawford R; Kaplan BL; Kaminski NE
Toxicol Sci; 2013 Feb; 131(2):419-33. PubMed ID: 23152191
[TBL] [Abstract][Full Text] [Related]
15. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
16. Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.
Lu H; Kaplan BL; Ngaotepprutaram T; Kaminski NE
J Leukoc Biol; 2009 Feb; 85(2):322-9. PubMed ID: 18988696
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.
Xie J; Xiao D; Xu Y; Zhao J; Jiang L; Hu X; Zhang Y; Yu L
Oncotarget; 2016 Feb; 7(6):6436-47. PubMed ID: 26824325
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction.
Robinson RH; Meissler JJ; Breslow-Deckman JM; Gaughan J; Adler MW; Eisenstein TK
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1239-50. PubMed ID: 23824763
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the role of CB
Li X; Hempel BJ; Yang HJ; Han X; Bi GH; Gardner EL; Xi ZX
Eur Neuropsychopharmacol; 2021 Feb; 43():38-51. PubMed ID: 33334652
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors.
Gaffal E; Cron M; Glodde N; Tüting T
Allergy; 2013 Aug; 68(8):994-1000. PubMed ID: 23889474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
